101 related articles for article (PubMed ID: 2885867)
1. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report.
Butler B; Bech P
Pharmacopsychiatry; 1987 May; 20(3):122-6. PubMed ID: 2885867
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
Möller HJ; Kissling W; Dietzfelbinger T; Stoll KD; Wendt G
Pharmacopsychiatry; 1989 Jan; 22(1):38-41. PubMed ID: 2565583
[TBL] [Abstract][Full Text] [Related]
3. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia.
Volz HP; Möller HJ; Gerebtzoff A; Bischoff S
Eur Arch Psychiatry Clin Neurosci; 2002 Apr; 252(2):76-80. PubMed ID: 12111340
[TBL] [Abstract][Full Text] [Related]
4. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients.
Wetzel H; Wiedemann K; Holsboer F; Benkert O
Psychopharmacology (Berl); 1991; 103(2):280-3. PubMed ID: 1674161
[TBL] [Abstract][Full Text] [Related]
5. Schizophrenia: D4 receptor elevation. What does it mean?
Seeman MV
J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
[No Abstract] [Full Text] [Related]
6. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
Chouinard G
J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
[TBL] [Abstract][Full Text] [Related]
7. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Klieser E; Lehmann E; Tegeler J
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
Klimke A; Klieser E
Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
Herrmann WM; Schärer E; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
[TBL] [Abstract][Full Text] [Related]
10. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
11. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
12. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
Wiesel FA
Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
[TBL] [Abstract][Full Text] [Related]
13. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
14. [Dopamine D2 and serotonin 5HT2 receptors: functions, interactions and clinical consequences in schizophrenia].
Guise S; Soubrouillard C; Blin O
Encephale; 1997 Apr; 23 Spec No 2():10-6. PubMed ID: 9273300
[TBL] [Abstract][Full Text] [Related]
15. Low-dose zotepine in the maintenance treatment of schizophrenia.
Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptors and the dopamine hypothesis of schizophrenia.
Seeman P
Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
[TBL] [Abstract][Full Text] [Related]
18. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Keegan D
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
[TBL] [Abstract][Full Text] [Related]
19. Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington G; Chong SA
J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
[TBL] [Abstract][Full Text] [Related]
20. [New chemotherapy approaches to psychoses].
Olié JP; Baylé FJ
Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
